P.D. El Farmaco de Noscira en Alzheimer ha demostrado ser uno de los pocos que realmente actuan frente al Alzheimer visto lo visto que hay a fecha de hoy en el mercado ... inicia ensayos de Fase II en Humanos este mismo Mes en Alemania .
********************************************************
Traduccion de parte de la Noticia en The Guardian :
VERANO DECISIVO
Zeltia estrella Yondelis fármaco, comercializado por PharmaMar su brazo con EE.UU. socio Johnson & Johnson, está a la espera de la aprobación de Europa y EE.UU. para tratar el cáncer de ovario este verano.
"Esto será un hito muy importante para la empresa", dijo Fernández Sousa.
Si se aprueba, Yondelis podría llegar al mercado para tratar el cáncer de ovario antes de fin de año, dan inicio a un potencial de ventas anuales de la droga de más de 1 mil millones de euros ($ 1,41 mil millones), dijo Fernández Sousa.
Yondelis, que se obtiene a partir de criaturas marinas, ya está vendida para el tratamiento de sarcoma de tejidos blandos y está siendo investigado a treast mama, pulmón y cánceres pediátricos.*************************************************
La New en The Guardian UK :guardian.co.uk
Zeltia seeks investors for Alzheimers' armBuzz up!
Reuters, Wednesday June 10 2009 * IPO for Alzheimer's arm still on cards, seeking investors
* To begin Phase II clinical trials in Germany in June
* Yondelis could be sold to treat ovarian cancer by year-end
(Adds detail)
MADRID, June 10 (Reuters) - Spanish biotechnology firm Zeltia is seeking foreign investors to take up shares in its Noscira arm, which is trying to find a cure for Alzheimers its chairman said on Wednesday.
Noscira will begin Phase II clinical trials on NYPTA in Germany in June after promising results in Phase I, and is already seeking a partner to license the drug outside of Europe.
"There are drugs sold for Alzheimer's for $5.6 billion a year but they don't cure. They just delay the disease's progression for three, six or twelve months," Jose Maria Fernandez Sousa told a Reuters Spanish small and mid cap forum.
NYPTA proved effective in curing damage caused by Alzheimers in pre-clinical trials, he said.
Noscira's financing needs are covered until February 2010, but a 25 million euros capital hike made at the beginning of the year was only half subscribed.
"Now we're looking for investors outside of Spain, in Germany, Switzerland, Britain and Scandinavia," Fernandez Sousa said at a Reuters Spanish small and mid cap forum.
A stock market listing for Noscira is still on the cards once market conditions improve, he added.
DECISIVE SUMMERZeltia's star drug Yondelis, marketed by its PharmaMar arm with U.S. partner Johnson & Johnson, is awaiting European and U.S. approval to treat ovarian cancer this summer.
"This will be a very important milestone for the company," Fernandez Sousa said.
If approved, Yondelis could reach the market to treat ovarian cancer before year-end, kicking off an annual sales potential for the drug of over 1 billion euros ($1.41 billion), Fernandez Sousa said.
Yondelis, which is derived from marine creatures, is already sold to treat soft tissue sarcoma and is being researched to treast breast, pediatric and lung cancers.
...
